12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

GlaxoSmithKline, Pfizer, Shionogi deal

ViiV Healthcare Ltd. acquired exclusive, worldwide rights to develop and commercialize a portfolio of HIV integrase inhibitors from Shionogi-ViiV Healthcare LLC, a JV between ViiV and Shionogi. The portfolio includes dolutegravir ( S/GSK1349572), for which worldwide regulatory submissions to treat HIV-1 infection are slated by year...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >